Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06319313 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Name: Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer — clinical trial record (NCT06319313)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorShanghai JMT-Bio Inc.

Started2024-05-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated March 20, 2024 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Shanghai JMT-Bio Inc.

31 trials monitored

See all monitored trials

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.

Trial Details

NCT Number	NCT06319313
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Squamous Cell Non-small Cell Lung Cancer
Enrollment	534 participants
Start Date	2024-05-01
Primary Completion	2026-07-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2024-03-20